Overcoming development and manufacturing challenges with lentiviral vectors

Scroll Down

As efficient and effective tools for gene transduction and delivering genes to target cell populations, viral vectors are helping drive the increasing popularity of cell and gene therapies (C&GTs). Commonly used viral vectors include adeno-associated virus (AAV), gamma retrovirus, and lentiviruses.

In C&GTs, lentiviruses are increasingly becoming the vector of choice for Chimeric Antigen Receptor T cell (CAR -T) therapies, offering high viral titers, as well as the ability to carry a large cassette and integrate the gene of interest into the host cell’s genome.

However, undertaking a lentiviral development and manufacturing project requires many factors to be considered at every stage of production. From plasmid design and pseudotyping to choosing between adherent and suspension cultures at upstream development, optimizing downstream purification methods, and performing the necessary analytical tests, each decision is critical.

With extensive expertise in lentiviral development and manufacturing, Genezen understands the importance of making the right choices throughout the lentivirus production process, helping to ensure the success of your project at all stages .

For insight into whether lentiviral vectors could be best suited for your next gene therapy project and the potential challenges that must be overcome to ensure success, download our lentiviral development and manufacturing whitepaper by completing the form to the right.

You may also be interested in...

Genezen completes cGMP-lentiviral and retroviral vector…

Genezen, a cell and gene therapy Contract Development and Manufacturing Organization...

Read more

Genezen announces launch of Scientific Advisory…

Leading experts in cell and gene therapy will provide guidance to...

Read more

Retroviruses in CAR-T therapies: From gamma…

Introduction In recent years, chimeric antigen receptor T (CAR-T) cells have...

Read more

EPR: 2022 biopharma trend predictions roundtable

From supply challenges surrounding COVID-19 to regulatory changes and innovations, the...

Read more